Skip to main content
Advertisement
Advertisement

MSLE

MSLE logo

Satellos Bioscience Inc. Common Stock

8.71
USD
Sponsored
+0.30
+3.57%
Sep 24, 15:59 UTC -4
Closed
exchange

Pre-Market

8.97

+0.26
+3.04%

MSLE Earnings Reports

Positive Surprise Ratio

MSLE beat 0 of 4 last estimates.

0%

Next Report

Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.55
Implied change from Q2 26 (Revenue/ EPS)
--
/
-1.79%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+57.14%

Satellos Bioscience Inc. Common Stock earnings per share and revenue

On Aug 13, 2026, MSLE reported earnings of -0.56 USD per share (EPS) for Q2 26, missing the estimate of -0.46 USD, resulting in a -20.90% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.14% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.55 USD, with revenue projected to reach -- USD, implying an decrease of -1.79% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
logo
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
logo
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
logo
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
logo
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
logo
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
For Q2 2026, Satellos Bioscience Inc. Common Stock reported EPS of -$0.56, missing estimates by -20.9%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.14%, changed from $9.82 before the earnings release to $9.61 the day after.
The next earning report is scheduled for Nov 03, 2026.
Based on -- analysts, Satellos Bioscience Inc. Common Stock is expected to report EPS of -$0.55 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement